IPSC Century Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1850119 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY1,556.5%
TTM net income YoY92.4%
TTM EPS YoY91.3%
Revenue 3-yr CAGR175.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-15.8%
Net margin-8.8%
FCF margin-95.9%
EBITDA margin-3.8%
Returns
ROE-6.0%
ROA-3.3%
ROIC (approx.)-13.8%
Asset turnover0.38x
Leverage & solvency
Liabilities / assets29.0%
Debt / equity0.00x
Current ratio5.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income10.85x
Accruals ratio32.7%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $109.16M | $6.59M | $2.23M | $5.20M | — |
| R&D expense | $95.67M | $107.24M | $92.71M | $97.17M | $75.65M |
| SG&A expense | $24.00M | $33.16M | $34.71M | $31.86M | $19.23M |
| Operating income | -$17.27M | -$138.14M | -$146.55M | -$133.83M | -$94.88M |
| Interest expense | — | — | $540,000 | $1.02M | $1.27M |
| Pretax income | -$9.65M | -$124.78M | -$134.79M | -$130.84M | -$95.78M |
| Income tax | -$68,000 | $1.79M | $1.88M | $91,000 | $43,000 |
| Net income | -$9.58M | -$126.57M | -$136.67M | -$130.93M | -$95.82M |
| EBITDA | -$4.17M | -$124.83M | -$133.50M | -$125.39M | -$91.14M |
| EPS (basic) | -0.14 | -1.61 | -2.30 | -2.27 | -2.96 |
| EPS (diluted) | -0.14 | -1.61 | -2.30 | -2.96 | -2.96 |
| Weighted avg. shares (diluted) | 86.56M | 78.65M | 59.31M | 32.39M | 32.39M |
| Balance sheet | |||||
| Cash & equivalents | $61.85M | $61.21M | $49.30M | $86.24M | $58.16M |
| Short-term investments | $55.26M | $130.85M | $125.41M | $231.23M | $166.43M |
| Current assets | $120.77M | $194.05M | $176.99M | $319.72M | $228.15M |
| PP&E, net | $50.03M | $62.14M | $71.70M | $82.78M | $57.97M |
| Intangibles | $34.20M | $34.20M | — | — | — |
| Total assets | $223.70M | $353.22M | $360.69M | $486.54M | $437.38M |
| Current liabilities | $20.23M | $129.78M | $17.85M | $29.82M | $15.65M |
| Short-term debt | — | — | — | $6.50M | $1.04M |
| Long-term debt | — | — | — | $3.74M | $8.90M |
| Total debt | — | — | — | $10.24M | $9.94M |
| Total liabilities | $64.77M | $191.85M | $175.94M | $183.81M | $41.14M |
| Shareholders' equity | $158.94M | $161.36M | $184.75M | $302.74M | $396.24M |
| Net debt | — | — | — | -$76.00M | -$48.22M |
| Shares outstanding | 87.52M | 85.84M | 60.34M | 55.01M | 58.47M |
| Cash flow statement | |||||
| Operating cash flow | -$103.88M | -$110.14M | -$88.35M | $14.05M | -$89.00M |
| Capital expenditure | $848,000 | $154,000 | $13.74M | $30.60M | $44.97M |
| Free cash flow | -$104.72M | -$110.29M | -$102.08M | -$16.55M | -$133.97M |
| Investing cash flow | $107.50M | $47.48M | $61.13M | -$13.13M | -$298.34M |
| Financing cash flow | $173,000 | $74.56M | -$9.72M | $27.16M | $417.77M |
| Depreciation & amortization | $13.10M | $13.30M | $13.04M | $8.44M | $3.75M |
| Stock-based compensation | $6.84M | $12.69M | $14.62M | $10.67M | $4.66M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.